AstraZeneca's Ultomiris Fails Late-Stage Trial in Stem Cell Transplant Blood Vessel Disorder

AstraZeneca said it is in ongoing discussions with global health authorities over potential next steps for the adult indication.

In ​a separate trial involving children, Ultomiris ⁠showed an overall ‌survival rate of 87.2% at 26 weeks ​and 73.4% ​at 52 weeks, and the drugmaker said it will ⁠advance regulatory filings for use in children.

The ​data comes on the heels of a failed ​pivotal heart-disease trial earlier this month, which have cast doubts over the drugmaker's trial design.

In May, a U.S. regulatory panel rejected its breast cancer drug camizestrant on trial design grounds.

AstraZeneca also reported that its experimental gastric cancer drug sonesitatug ‌vedotin met a key goal, showing a statistically significant and clinically meaningful improvement in overall survival in advanced ​gastric cancer ​patients.

The drugmaker, ⁠which topped second-quarter profit expectations on strong demand for its cancer and rare disease therapies, is counting on up to 20 new drug ​launches to help generate $80 billion in annual revenue by 2030.

Ultomiris, known chemically as ravulizumab, is already approved in the United States, the EU and Japan for treating certain rare blood disorders and neurological conditions.